Poseida Therapeutics, Inc.
PSTX · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $71,748 | $25,973 | $28,142 | $24,995 |
| % Growth | 176.2% | -7.7% | 12.6% | – |
| Cost of Goods Sold | $0 | $1,349 | $1,380 | $4,176 |
| Gross Profit | $71,748 | $24,624 | $26,762 | $20,819 |
| % Margin | 100% | 94.8% | 95.1% | 83.3% |
| R&D Expenses | $41,914 | $44,198 | $41,541 | $42,046 |
| G&A Expenses | $10,092 | $12,182 | $9,798 | $8,860 |
| SG&A Expenses | $10,092 | $12,182 | $9,798 | $8,860 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $52,006 | $56,380 | $51,339 | $50,906 |
| Operating Income | $19,742 | -$31,756 | -$24,577 | -$25,911 |
| % Margin | 27.5% | -122.3% | -87.3% | -103.7% |
| Other Income/Exp. Net | $536 | $385 | $303 | $560 |
| Pre-Tax Income | $20,278 | -$31,371 | -$24,274 | -$25,349 |
| Tax Expense | $43 | $0 | $0 | $0 |
| Net Income | $20,235 | -$31,371 | -$24,274 | -$23,990 |
| % Margin | 28.2% | -120.8% | -86.3% | -96% |
| EPS | 0.21 | -0.32 | -0.25 | -0.27 |
| % Growth | 165.6% | -28% | 7.4% | – |
| EPS Diluted | 0.21 | -0.32 | -0.25 | -0.27 |
| Weighted Avg Shares Out | 97,160 | 96,965 | 96,020 | 90,185 |
| Weighted Avg Shares Out Dil | 98,220 | 96,965 | 96,020 | 90,185 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2,295 | $2,259 | $2,253 | $2,267 |
| Depreciation & Amortization | $1,319 | $1,349 | $1,380 | $1,438 |
| EBITDA | $23,892 | -$27,763 | -$20,641 | -$21,644 |
| % Margin | 33.3% | -106.9% | -73.3% | -86.6% |